• SPX
  • $5,957.50
  • 0.15 %
  • $8.79
  • DJI
  • $44,195.21
  • 0.74 %
  • $324.85
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,266.48
  • 1.44 %
  • $117.21
  • IXIC
  • $18,951.45
  • -0.11 %
  • -$20.97
Processa Pharmaceuticals, Inc. (PCSA) Stock Price, News & Analysis

Processa Pharmaceuticals, Inc. (PCSA) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.88

-$0

(0%)

Day's range
$0.86
Day's range
$0.93
50-day range
$0.85
Day's range
$1.47
  • Country: US
  • ISIN: US74275C3043
52 wk range
$0.85
Day's range
$17.4
  • CEO: Mr. George K. Ng Esq., J.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -29.49
  • Piotroski Score 1.00
  • Grade Buy
  • Symbol (PCSA)
  • Company Processa Pharmaceuticals, Inc.
  • Price $0.88
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $0.86
  • Day High $0.93
  • Year High $17.40

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $9.00
  • High Stock Price Target $9.00
  • Low Stock Price Target $9.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$6.06
  • Trailing P/E Ratio -0.27
  • Forward P/E Ratio -0.27
  • P/E Growth -0.27
  • Net Income $-11,121,520

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Processa Pharmaceuticals, Inc. Frequently Asked Questions

  • What is the Processa Pharmaceuticals, Inc. stock price today?

    Today's price of Processa Pharmaceuticals, Inc. is $0.88 — it has decreased by 0% in the past 24 hours. Watch Processa Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Processa Pharmaceuticals, Inc. release reports?

    Yes, you can track Processa Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Processa Pharmaceuticals, Inc. stock forecast?

    Watch the Processa Pharmaceuticals, Inc. chart and read a more detailed Processa Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Processa Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Processa Pharmaceuticals, Inc. stock ticker.

  • How to buy Processa Pharmaceuticals, Inc. stocks?

    Like other stocks, PCSA shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Processa Pharmaceuticals, Inc.'s EBITDA?

    Processa Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Processa Pharmaceuticals, Inc.’s financial statements.

  • What is the Processa Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Processa Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Processa Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Processa Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Processa Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Processa Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.